Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.
The COBAS AMPLICOR hepatitis B virus assay targets a conserved region of the genome and is widely used to monitor treatment of hepatitis B in order to identify emerging resistance. However, the assay failed to recognize increasing viremia levels when YMDD mutations were paralleled by mutations in the segment targeted by the COBAS AMPLICOR probe.
Lindh
Magnus
M
Department of Clinical Virology, Göteborg University, Guldhedsgatan 10 B, 413 46 Göteborg, Sweden. magnus.lindh@microbio.gu.se
Hannoun
Charles
C
Malmström
Sebastian
S
Lindberg
Johan
J
Norkrans
Gunnar
G
D000998:Antiviral Agents / Q000494:pharmacology; D001483:Base Sequence; D015342:DNA Probes; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005188:False Negative Reactions; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation; D011933:Reagent Kits, Diagnostic; D017422:Sequence Analysis, DNA; D019562:Viral Load
D000998:Antiviral Agents; D015342:DNA Probes; D004279:DNA, Viral; D011933:Reagent Kits, Diagnostic; D019259:Lamivudine